Regulatory FDA delays decision on Sanofi’s subcutaneous Sarclisa PharmaphorumThe FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.RegulatoryOncologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex. RegulatoryOncologyRead full story Post navigation Previous: MSD-backed Ray locks in $125m to back eye drug pipelineNext: Lilly exits Rigel alliance, adding to RIPK1 scrap heap Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
